Work

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations

Year: 2024

Type: article

Study design: Study Protocol

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2023.12.010

Authors: Delvys Rodriguez-Abreu, Joaquim Bosch-Barrera, Jhanelle E. Gray, Myung-Ju Ahn, Melissa Johnson, Xinwei Yu, Saad Mohammad, Xueying Chen, Trever Todd, Jongseok Kim, Martin Reck

Institutions: Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Universitat de Girona, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona, Moffitt Cancer Center, Samsung Medical Center, Sungkyunkwan University, Sarah Cannon, Gilead Sciences (United States), Arcus Biosciences (United States), German Center for Lung Research, LungenClinic Grosshansdorf

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4390639385

FWCI: 2.292

Cites: 16

Cited by: 15

Related to: 10